Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by ikfe-CRO GmbH.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Novartis Pharmaceuticals
IKFE Institute for Clinical Research and Development
Information provided by (Responsible Party):
ikfe-CRO GmbH
ClinicalTrials.gov Identifier:
NCT01565096
First received: March 23, 2012
Last updated: March 26, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)